Anaphylaxis and Coronavirus Disease 2019 Vaccine: A Danger Relationship?

COVID-19, coronavirus disease 2019.

Authors and Disclosures

Luciana Kase Tanno^a,b,c, Mariana Castells^d, Marco Caminati^e, Gianenrico Senna^e,f and Pascal Demoly<sup>a,b

a</sup>Institut Desbrest d'Epidémiologie et de Santé Publique, IDESP UMR UA11 INSERM, University of Montpellier, ^bWHO Collaborating Center for Classification Scientific Support, University Hospital of Montpellier, Montpellier, France, ^cHospital Sirio-Libanês, São Paulo, Brazil, ^dDivision of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts, USA, ^eDepartment of Medicine, University of Verona and ^fAllergy Unit and Asthma Center, University of Verona and Verona University Hospital, Verona, Italy

Correspondence to
Luciana Kase Tanno, MD, PhD, Division of Allergy, Department of Pulmonology, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, 371 av. du Doyen Gaston Giraud, 34295 Montpellier cedex 5, France. Tel: +33 467336107; fax: +33 467633645; e-mail: luciana.tanno@gmail.com

Conflicts of interest
There are no conflicts of interest.

Sidebar

Key Points

• Vaccines against coronavirus disease 2019 are an essential global intervention to control the current pandemic situation.

• Anaphylactic reactions have been reported after SARSCoV2 RNA vaccines, supposedly related to one of its components: the polyethylene glycol, with no convincing proof so far.

• Anaphylaxis due to vaccine is extremely rare, estimated at 2.5–11/1 000 000 in the context of vaccine safety surveillance programs.

• The only recommendation should be addressed to patients who experienced prior allergic reaction to the vaccine in question or its components.

• Specific cases should receive individualized investigation and care.